NIKKEI 225
27,999.87 -162.96 (-0.58%) HANG SENG
17,957.81 +659.87 (+3.81%) CRUDE OIL
78.13 +0.89 (+1.15%) GOLD FUTURES
1,748.90 +8.60 (+0.49%) DOW
33,849.46 -497.57 (-1.45%) BTC-GBP
13,581.73 +36.78 (+0.27%)
BioPorto A/S (BIOPOR.CO)
| Previous close | 2.4950 |
| Open | 2.5000 |
| Bid | 2.5500 x 0 |
| Ask | 2.5700 x 0 |
| Day's range | 2.5000 - 2.6650 |
| 52-week range | 1.0020 - 3.2700 |
| Volume | |
| Avg. volume | 630,420 |
| Market cap | 853.434M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2140 |
| Earnings date | 09 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
- Globe Newswire
Resolutions of the Extraordinary General Meeting of BioPorto A/S
November 23, 2022 Announcement no. 17 Resolutions of the Extraordinary General Meeting of BioPorto A/S COPENHAGEN, DENMARK and BOSTON, MA, USA, November 23, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) today held an Extraordinary General Meeting with the following results: Deloitte Statsautoriseret Revisionspartnerselskab, company registration number 33963556, was elected as the Company’s new auditor.The chair of the general meeting, with a right of substitution, was
- Globe Newswire
Correction: BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration
November 10, 2022 Announcement no. 16 BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration COPENHAGEN, DENMARK and BOSTON, MA, USA, November 10, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) has announced the submission of a De Novo application to the US Food and Drug Administration (FDA) of a neutrophil gelatinase-associated lipocalin (NGAL) test to aid in identifying pediatric patients (≥3 months to <22 years)
- Globe Newswire
BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration
November 10, 2022 Announcement no. 16 BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration COPENHAGEN, DENMARK and BOSTON, MA, USA, November 10, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) has announced the submission of a De Novo application to the US Food and Drug Administration (FDA) of a neutrophil gelatinase-associated lipocalin (NGAL) test to aid in identifying pediatric patients (≥3 months to <22 years)
